Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Mohamed Elsafy։ Rethinking Hemostatic Management in Glanzmann Thrombasthenia with Sutacimig
Apr 7, 2026, 16:06

Mohamed Elsafy։ Rethinking Hemostatic Management in Glanzmann Thrombasthenia with Sutacimig

Mohamed Elsafy, Drug Safety and Pharmacovigilance Lead Physician, Global Safety Strategy and Governance at ClinRM LLC, shared a post on LinkedIn:

”Sutacimig represents a novel and potentially transformative approach in Glanzmann thrombasthenia, shifting the paradigm from reactive bleeding management to true prophylaxis.

By leveraging a bispecific mechanism to localize and stabilize endogenous Factor VIIa at the platelet surface, this strategy directly addresses the underlying hemostatic defect. Early data showing meaningful reductions in bleeding burden are encouraging, particularly in a setting with no established preventive options.

If sustained in later-stage studies, this could redefine the standard of care in rare platelet disorders.”

Stay updated with Hemostasis Today.